GlassScriptPhysician profile
Deepak Bhamidipati
NPI 1912402413
$2,194.25
in general payments reported to CMS, 2019-2025
33 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $146 · 2024: $491 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043 · Education: $31.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.14 |
| Education | $31.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $246.30 | 2024-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $188.03 | 2025 | Calquence, Enhertu, Imfinzi |
| Celgene Corporation | $186.56 | 2023-2025 | Pomalyst, Breyanzi, Reblozyl |
| Array Biopharma INC | $151.04 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $141.29 | 2025 | Opdivo, Opdualag |
| Rigel Pharmaceuticals, INC. | $141.11 | 2022-2025 | Tavalisse, Gavreto, Rezlidhia |
| Merck Sharp & Dohme LLC | $130.69 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $119.97 | 2025 | Libtayo |
| Amgen INC. | $81.38 | 2024 | Vectibix |
| Pfizer INC. | $67.53 | 2023-2025 | |
| Springworks Therapeutics, INC. | $66.17 | 2025 | Gomekli, Ogsiveo |
| Genentech USA, INC. | $50.89 | 2024-2025 | Lunsumio, Phesgo, Perjeta |
| Genmab U.S., INC. | $49.53 | 2024-2025 | Epkinly |
| Tempus Ai, INC | $44.31 | 2024-2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $43.88 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $42.32 | 2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $39.52 | 2024-2025 | |
| Beigene USA, INC. | $39.40 | 2024 | Tevimbra, Brukinsa |
| Glaxosmithkline, LLC. | $38.22 | 2025 | Ojjaara |
| Abbvie INC. | $34.22 | 2024 | |
| Caris Mpi, INC. | $33.77 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $32.68 | 2025 | Enjaymo |
| Lilly USA, LLC | $25.77 | 2024 | Jaypirca, Retevmo, Verzenio |
| Astellas Pharma US INC | $25.18 | 2025 | Xtandi |
| Incyte Corporation | $21.10 | 2025 | Monjuvi, Pemazyre |
| Ipsen Biopharmaceuticals, INC | $20.81 | 2025 | Onivyde |
| Servier Pharmaceuticals LLC | $20.49 | 2024 | |
| Invivyd INC | $20.20 | 2025 | Pemgarda |
| Tersera Therapeutics LLC | $19.90 | 2025 | Zoladex |
| Janssen Biotech, INC. | $18.97 | 2025 | Rybrevant |
| Sun Pharmaceutical Industries INC. | $18.65 | 2024 | |
| Pharmaessentia USA Corporation | $18.21 | 2025 | Besremi |
| Sobi, INC | $16.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Bhamidipati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.